WHAT IS CLAIMED IS:

1. An isolated bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:760.

2. A pharmaceutical composition comprising the bacteriophage of claim 1 and a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2, comprising a bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:2 further comprising one or more additional bacteriophages effective against *Enterococcus faecalis* or *Enterococcus faecium.*

4. The pharmaceutical composition of claim 2, comprising a bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:2 further comprising one or more additional bacteriophages effective against bacteria other than *Enterococcus faecalis* or *Enterococcus faecium.*

5. The pharmaceutical composition of claim 2, comprising a bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:3 further comprising one or more additional bacteriophages effective against *Pseudomonas aeruginosa.*

6. The pharmaceutical composition of claim 2, comprising a bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:3 further comprising one or more additional bacteriophages effective against bacteria other than *Pseudomonas aeruginosa.*

7. The pharmaceutical composition of claim 2, comprising a bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7 further comprising one or more additional bacteriophages effective against *Staphylococcus aureus.*

8. The pharmaceutical composition of claim 2, comprising a bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7 further comprising one or more additional bacteriophages effective against bacteria other than *Staphylococcus aureus.*

9. The pharmaceutical composition of claim 2, comprising a bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:760 further comprising one or more additional bacteriophages effective against *Acinetobacter baumannii.*

10. The pharmaceutical composition of claim 2, comprising a bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:760 further comprising one or more additional bacteriophages effective against bacteria other than *Acinetobacter baumannii.*

11. An isolated lysin protein from bacteriophage F1245/05, F170/08, F197/08, F86/06, F87s/06 or F91a/06, or a fragment thereof having antibacterial or antimicrobial activity against one or more of *Acinetobacter baumanii, Enterococcus faecalis, Enterococcus faecium* and *Staphylococcus aureus.*

12. The isolated lysin protein of claim 11, said protein having the amino acid sequence of SEQ ID NO:184, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:446, SEQ ID NO:447, SEQ ID NO:448, SEQ ID NO:575, SEQ ID NO:641, SEQ ID NO:712, SEQ ID NO: 797, or a fragment thereof, which fragment has antibacterial or antimicrobial activity against one or more of *Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus* and *Acinetobacter baumanii.*

13. An isolated first protein having at least 85% sequence identity to a second protein of the same size, wherein said first protein has antibacterial or antimicrobial activity against one or more of *Acinetobacter baumanii, Enterococcus faecalis, Enterococcus faecium* and *Staphylococcus aureus* and said second protein has the amino acid sequence of SEQ ID NO: 797, SEQ ID NO:184, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:446, SEQ ID NO:447, SEQ ID NO:448, SEQ ID NO:575, SEQ ID NO:641, SEQ ID NO:712 or a fragment thereof.

14. The isolated first protein of claim 13 having at least 95% sequence identity to said second protein.

15. The fragment of claim 11, wherein said fragment is a CHAP domain isolated from a polypeptide having the amino acid sequence of SEQ ID NO:184, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:446, SEQ ID NO:447, SEQ ID NO:448, SEQ ID NO:575, SEQ ID NO:641 or SEQ ID NO:712.

16. The fragment of claim 15, wherein said fragment has the amino acid sequence of SEQ ID NO:755, SEQ ID NO:756, SEQ ID NO:757, SEQ ID NO:758 or SEQ ID NO:759.

17. An isolated tail tape measure protein or tail protein from bacteriophage, F170/08, F770/05, F197/08, F86/06, F87s/06, F91a/06, or F1245/05, or a fragment thereof having antibacterial or antimicrobial activity against one or more of *Acinetobacter baumanni, Enterococcus faecalis, Enterococcus faecium, Pseudomonas aeruginosa* and *Staphylococcus aureus*.

18. The isolated tail tape measure protein or tail protein of claim 17, said protein having the amino acid sequence of SEQ ID NO:204, SEQ ID NO:214, SEQ ID NO:435, SEQ ID NO:438, SEQ ID NO:440, SEQ ID NO:525, SEQ ID NO:526, SEQ ID NO:527, SEQ ID NO:528, SEQ ID NO:529, SEQ ID NO:530, SEQ ID NO:531, SEQ ID NO:532, SEQ ID NO:533, SEQ ID NO:534, SEQ ID NO:535, SEQ ID NO:536, SEQ ID NO:537, SEQ ID NO:538, SEQ ID NO:539, SEQ ID NO:567, SEQ ID NO:568, SEQ ID NO:632, SEQ ID NO:633, SEQ ID NO:700, SEQ ID NO:701, SEQ ID NO:702, SEQ ID NO:703, SEQ ID NO:704, SEQ ID NO:795, or a fragment thereof, which fragment has antibacterial or antimicrobial activity against one or more of *Acinetobacter baumanni, Enterococcus faecalis, Enterococcus faecium, Pseudomonas aeruginosa* and *Staphylococcus aureus*.

19. An isolated first protein having at least 85% sequence identity to a second protein of the same size, wherein said first protein has a biological activity associated with bacteriophage F170/08, F770/05, F197/08, F86/06, F87s/06, F91a/06, or F1245/05 and said second protein has the amino acid sequence of SEQ ID NO:204, SEQ ID NO:214, SEQ ID NO:435, SEQ ID NO:438, SEQ ID NO:440, SEQ ID NO:525, SEQ ID NO:526, SEQ ID NO:527, SEQ ID NO:528, SEQ ID NO:529, SEQ ID NO:530, SEQ ID NO:531, SEQ ID NO:532, SEQ ID NO:533, SEQ ID NO:534, SEQ ID NO:535, SEQ ID NO:536, SEQ ID NO:537, SEQ ID NO:538, SEQ ID NO:539, SEQ ID NO:567, SEQ ID NO:568, SEQ ID NO:632, SEQ ID NO:633, SEQ ID NO:700, SEQ ID NO:701, SEQ ID NO:702, SEQ ID NO:703, SEQ ID NO:704, SEQ ID NO:795, or a fragment thereof.

20. The isolated first protein of claim 19 having at least 95% sequence identity to said second protein.

21. A pharmaceutical composition comprising the isolated protein of claim 11 or 17 and a pharmaceutically acceptable carrier.

22. The pharmaceutical composition of claim 21, comprising an isolated protein having the amino acid sequence of SEQ ID NO:184, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204 or SEQ ID NO:214, or a fragment thereof, having antibacterial or antimicrobial activity against *Enterococcus faecalis* or *Enterococcus faecium*, further comprising one or more bacteriophages or additional proteins effective against *Enterococcus faecalis* or *Enterococcus faecium.*

23. The pharmaceutical composition of claim 21, comprising an isolated protein having the amino acid sequence of SEQ ID NO:184, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204 or SEQ ID NO:214, or a fragment thereof, having antibacterial or antimicrobial activity against *Enterococcus faecalis* or *Enterococcus faecium*, further comprising one or more bacteriophages or additional proteins effective against bacteria other than *Enterococcus faecalis* or *Enterococcus faecium.*

24. The pharmaceutical composition of claim 21, comprising an isolated protein having the amino acid sequence of SEQ ID NO:435 or SEQ ID NO:438, or a fragment, variant or derivative thereof having antibacterial or antimicrobial activity against *Pseudomonas aeruginosa*, further comprising one or more bacteriophages or additional proteins effective against *Pseudomonas aeruginosa.*

25. The pharmaceutical composition of claim 21, comprising an isolated protein having the amino acid sequence of SEQ ID NO:435 or SEQ ID NO:438, or a fragment, variant or derivative thereof having antibacterial or antimicrobial activity against *Pseudomonas aeruginosa*, further comprising one or more bacteriophages or additional proteins effective against bacteria other than *Pseudomonas aeruginosa.*

26. The pharmaceutical composition of claim 21, comprising an isolated protein having the amino acid sequence of SEQ ID NO:440, SEQ ID NO:525, SEQ ID NO:526, SEQ ID NO:527, SEQ ID NO:528, SEQ ID NO:529, SEQ ID NO:530, SEQ ID NO:531, SEQ ID NO:532, SEQ ID NO:533, SEQ ID NO:534, SEQ ID NO:535, SEQ ID NO:536, SEQ ID

NO:537, SEQ ID NO:538, SEQ ID NO:539, SEQ ID NO:567, SEQ ID NO:568, SEQ ID NO:632,SEQ ID NO:633, SEQ ID NO:700, SEQ ID NO:701, SEQ ID NO:702, SEQ ID NO:703, SEQ ID NO:704 or a fragment, variant or derivative thereof having antibacterial or antimicrobial activity against *Staphylococcus aureus*, further comprising one or more bacteriophages or additional proteins effective against *Staphylococcus aureus.*

27. The pharmaceutical composition of claim 21, comprising an isolated protein having the amino acid sequence of SEQ ID NO:440, SEQ ID NO:525, SEQ ID NO:526, SEQ ID NO:527, SEQ ID NO:528, SEQ ID NO:529, SEQ ID NO:530, SEQ ID NO:531, SEQ ID NO:532, SEQ ID NO:533, SEQ ID NO:534, SEQ ID NO:535, SEQ ID NO:536, SEQ ID NO:537, SEQ ID NO:538, SEQ ID NO:539, SEQ ID NO:567, SEQ ID NO:568, SEQ ID NO:632,SEQ ID NO:633, SEQ ID NO:700, SEQ ID NO:701, SEQ ID NO:702, SEQ ID NO:703, SEQ ID NO:704, or a fragment, variant or derivative thereof having antibacterial or antimicrobial activity against *Staphylococcus aureus*, further comprising one or more bacteriophages or additional proteins effective against bacteria other than *Staphylococcus aureus.*

28. The pharmaceutical composition of claim 21, comprising an isolated protein having the amino acid sequence of SEQ ID NOS:761-816, or a fragment, variant or derivative thereof having antibacterial or antimicrobial activity against *Acinetobacter baumannii*, further comprising one or more bacteriophages or additional proteins effective against *Acinetobacter baumannii.*

29. The pharmaceutical composition of claim 21, comprising an isolated protein having the amino acid sequence of SEQ ID NOS:761-816, or a fragment, variant or derivative thereof having antibacterial or antimicrobial activity against *Acinetobacter baumannii*, further comprising one or more bacteriophages or additional proteins effective against bacteria other than *Acinetobacter baumannii.*

30. An isolated nucleic acid comprising a nucleotide sequence encoding the protein of claim 11 or 17.

31. Use of the pharmaceutical composition of claim 2 or 21 in the manufacture of a medicament for treating or preventing a bacterial infection in a subject in need thereof.

32. The use of claim 31 wherein said bacterial infection is an infection by one or more of *Acinetobacter baumanni, Enterococcus faecalis*, *Enterococcus faecium*, *Pseudomonas aeruginosa* and *Staphylococcus aureus*.

33. The use of claim 31 wherein said bacterial infection is an infection by a bacterium other than *Acinetobacter baumanni, Enterococcus faecalis*, *Enterococcus faecium*, *Pseudomonas aeruginosa* and *Staphylococcus aureus*.

34. The use of claim 31, wherein the infection is a nosocomial infection.

35. The use of claim 31, wherein the composition is administered topically.

36. The use of claim 31, wherein the subject is a mammal.

37. The use of claim 36, wherein the mammal is a human.

38. The use of claim 31, wherein the infection treated is an infection of the skin.

39. The use of claim 38, wherein said infection of the skin is an infection associated with a diabetic foot ulcer.

40. A method for diagnosing the causative agent of a bacterial infection comprising:

(i) culturing a tissue sample from a patient;

(ii) contacting the culture of step (i) with the bacteriophage of claim 1, or protein of claim 11 or 17; and

(iii) monitoring for evidence of growth or lysis of the culture;

wherein evidence of lysis of the culture indicatives that the culture comprises a species or strain of bacteria that is known to be susceptible to the bacteriophage or protein used in step (ii).

41. The method of claim 40, wherein the tissue sample is a sample of blood, fluid, tissue biopsy or swab collected from said patient.

42. A method for reducing or inhibiting the colonization or growth of bacteria on a solid surface comprising contacting said solid surface with the bacteriophage of claim 1, or protein of claim 11 or 17.

43. The method of claim 42, wherein said solid surface is the surface of a hospital apparatus or a piece of hospital equipment.

44. The method of claim 43, wherein said apparatus or equipment is a surgical apparatus or piece of surgical equipment.

45. Use of a bacteriophage of claim 1, or protein of claim 11 or 17, in the manufacture of a medicament for reducing or inhibiting an infection associated with the colonization or growth on a biological surface of a mammal of one or more of *Acinetobacter baumanni, Enterococcus faecalis, Enterococcus faecium, Pseudomonas aeruginosa* and *Staphylococcus aureus*.

46. The use of claim 45, wherein said surface is the skin or a mucus membrane of a mammal.

47. The use of claim 46, wherein said mammal is a human.

WHAT IS CLAIMED IS:

1. An isolated bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:760.

2. A pharmaceutical composition comprising the bacteriophage of claim 1 and a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2, comprising a bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:2 further comprising one or more additional bacteriophages effective against *Enterococcus faecalis* or *Enterococcus faecium.*

4. The pharmaceutical composition of claim 2, comprising a bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:2 further comprising one or more additional bacteriophages effective against bacteria other than *Enterococcus faecalis* or *Enterococcus faecium.*

5. The pharmaceutical composition of claim 2, comprising a bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:3 further comprising one or more additional bacteriophages effective against *Pseudomonas aeruginosa.*

6. The pharmaceutical composition of claim 2, comprising a bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:3 further comprising one or more additional bacteriophages effective against bacteria other than *Pseudomonas aeruginosa.*

7. The pharmaceutical composition of claim 2, comprising a bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7 further comprising one or more additional bacteriophages effective against *Staphylococcus aureus.*

8. The pharmaceutical composition of claim 2, comprising a bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID

NO:6 or SEQ ID NO:7 further comprising one or more additional bacteriophages effective against bacteria other than *Staphylococcus aureus*.

9. The pharmaceutical composition of claim 2, comprising a bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:760 further comprising one or more additional bacteriophages effective against *Acinetobacter baumannii*.

10. The pharmaceutical composition of claim 2, comprising a bacteriophage having a genome which comprises the nucleic acid sequence of SEQ ID NO:760 further comprising one or more additional bacteriophages effective against bacteria other than *Acinetobacter baumannii*.

11. An isolated lysin protein from bacteriophage F1245/05, F168/08, F170/08, F197/08, F86/06, F87s/06 or F91a/06, or a fragment, variant or derivative thereof having antibacterial or antimicrobial activity against one or more of *Acinetobacter baumanii, Enterococcus faecalis*, *Enterococcus faecium* and *Staphylococcus aureus*.

12. The isolated lysin protein of claim 11, said protein having the amino acid sequence of SEQ ID NO:68, SEQ ID NO:184, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:446, SEQ ID NO:447, SEQ ID NO:448, SEQ ID NO:575, SEQ ID NO:641, SEQ ID NO:712, SEQ ID NO: 797, or a fragment, variant or derivative thereof, which fragment, variant or derivative has antibacterial or antimicrobial activity against one or more of *Enterococcus faecalis*, *Enterococcus faecium*, *Staphylococcus aureus* and *Acinetobacter baumanii*.

13. An isolated first protein having at least 85% sequence identity to a second protein of the same size, wherein said first protein has antibacterial or antimicrobial activity against one or more of *Acinetobacter baumanii, Enterococcus faecalis*, *Enterococcus faecium* and *Staphylococcus aureus* and said second protein has the amino acid sequence of SEQ ID NO: 797, SEQ ID NO:68, SEQ ID NO:184, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:446, SEQ ID NO:447, SEQ ID NO:448, SEQ ID NO:575, SEQ ID NO:641, SEQ ID NO:712 or a fragment thereof.

14. The isolated first protein of claim 13 having at least 95% sequence identity to said second protein.

15. The fragment of claim 11, wherein said fragment is a CHAP domain isolated from a polypeptide having the amino acid sequence of SEQ ID NO:68, SEQ ID NO:184, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:446, SEQ ID NO:447, SEQ ID NO:448, SEQ ID NO:575, SEQ ID NO:641 or SEQ ID NO:712.

16. The fragment of claim 15, wherein said fragment has the amino acid sequence of SEQ ID NO:755, SEQ ID NO:756, SEQ ID NO:757, SEQ ID NO:758 or SEQ ID NO:759.

17. An isolated tail tape measure protein or tail protein from bacteriophage F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06, F91a/06, or F1245/05, or a fragment, variant or derivative thereof having a biological activity associated with the bacteriophage from which it was isolated.

18. The isolated tail tape measure protein or tail protein of claim 17, said protein having the amino acid sequence of SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:204, SEQ ID NO:214, SEQ ID NO:435, SEQ ID NO:438, SEQ ID NO:440, SEQ ID NO:525, SEQ ID NO:526, SEQ ID NO:527, SEQ ID NO:528, SEQ ID NO:529, SEQ ID NO:530, SEQ ID NO:531, SEQ ID NO:532, SEQ ID NO:533, SEQ ID NO:534, SEQ ID NO:535, SEQ ID NO:536, SEQ ID NO:537, SEQ ID NO:538, SEQ ID NO:539, SEQ ID NO:567, SEQ ID NO:568, SEQ ID NO:632, SEQ ID NO:633, SEQ ID NO:700, SEQ ID NO:701, SEQ ID NO:702, SEQ ID NO:703, SEQ ID NO:704, SEQ ID NO:795, or a fragment, variant or derivative thereof, which fragment, variant or derivative has a biological activity associated with the bacteriophage from which it was isolated or derived.

19. An isolated first protein having at least 85% sequence identity to a second protein of the same size, wherein said first protein has a biological activity associated with bacteriophage F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06, F91a/06, or F1245/05 and said second protein has the amino acid sequence of SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:204, SEQ ID NO:214, SEQ ID NO:435, SEQ ID NO:438, SEQ ID NO:440, SEQ ID NO:525, SEQ ID NO:526, SEQ ID NO:527, SEQ ID NO:528, SEQ ID NO:529, SEQ ID NO:530, SEQ ID NO:531, SEQ ID NO:532, SEQ ID NO:533, SEQ ID NO:534, SEQ ID NO:535, SEQ ID NO:536, SEQ ID NO:537, SEQ ID NO:538, SEQ ID NO:539, SEQ ID NO:567, SEQ ID

NO:568, SEQ ID NO:632, SEQ ID NO:633, SEQ ID NO:700, SEQ ID NO:701, SEQ ID NO:702, SEQ ID NO:703, SEQ ID NO:704, SEQ ID NO:795,or a fragment thereof.

20. The isolated first protein of claim 19 having at least 95% sequence identity to said second protein.

21. A pharmaceutical composition comprising the isolated protein of claim 11 or 17 and a pharmaceutically acceptable carrier.

22. The pharmaceutical composition of claim 21, comprising an isolated protein having the amino acid sequence of SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:68, SEQ ID NO:184, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204 or SEQ ID NO:214, or a fragment, variant or derivative thereof having antibacterial or antimicrobial activity against *Enterococcus faecalis* or *Enterococcus faecium*, further comprising one or more bacteriophages or additional proteins effective against *Enterococcus faecalis* or *Enterococcus faecium*.

23. The pharmaceutical composition of claim 21, comprising an isolated protein having the amino acid sequence of SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:68, SEQ ID NO:184, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204 or SEQ ID NO:214, or a fragment, variant or derivative thereof having antibacterial or antimicrobial activity against *Enterococcus faecalis* or *Enterococcus faecium*, further comprising one or more bacteriophages or additional proteins effective against bacteria other than *Enterococcus faecalis* or *Enterococcus faecium*.

24. The pharmaceutical composition of claim 21, comprising an isolated protein having the amino acid sequence of SEQ ID NO:435 or SEQ ID NO:438, or a fragment, variant or derivative thereof having antibacterial or antimicrobial activity against *Pseudomonas aeruginosa*, further comprising one or more bacteriophages or additional proteins effective against *Pseudomonas aeruginosa*.

25. The pharmaceutical composition of claim 21, comprising an isolated protein having the amino acid sequence of SEQ ID NO:435 or SEQ ID NO:438, or a fragment, variant or derivative thereof having antibacterial or antimicrobial activity against *Pseudomonas aeruginosa*, further comprising one or more bacteriophages or additional proteins effective against bacteria other than *Pseudomonas aeruginosa*.

26. The pharmaceutical composition of claim 21, comprising an isolated protein having the amino acid sequence of SEQ ID NO:440, SEQ ID NO:525, SEQ ID NO:526, SEQ ID NO:527, SEQ ID NO:528, SEQ ID NO:529, SEQ ID NO:530, SEQ ID NO:531, SEQ ID NO:532, SEQ ID NO:533, SEQ ID NO:534, SEQ ID NO:535, SEQ ID NO:536, SEQ ID NO:537, SEQ ID NO:538, SEQ ID NO:539, SEQ ID NO:567, SEQ ID NO:568, SEQ ID NO:632,SEQ ID NO:633, SEQ ID NO:700, SEQ ID NO:701, SEQ ID NO:702, SEQ ID NO:703, SEQ ID NO:704 or a fragment, variant or derivative thereof having antibacterial or antimicrobial activity against *Staphylococcus aureus*, further comprising one or more bacteriophages or additional proteins effective against *Staphylococcus aureus*.

27. The pharmaceutical composition of claim 21, comprising an isolated protein having the amino acid sequence of SEQ ID NO:440, SEQ ID NO:525, SEQ ID NO:526, SEQ ID NO:527, SEQ ID NO:528, SEQ ID NO:529, SEQ ID NO:530, SEQ ID NO:531, SEQ ID NO:532, SEQ ID NO:533, SEQ ID NO:534, SEQ ID NO:535, SEQ ID NO:536, SEQ ID NO:537, SEQ ID NO:538, SEQ ID NO:539, SEQ ID NO:567, SEQ ID NO:568, SEQ ID NO:632,SEQ ID NO:633, SEQ ID NO:700, SEQ ID NO:701, SEQ ID NO:702, SEQ ID NO:703, SEQ ID NO:704, or a fragment, variant or derivative thereof having antibacterial or antimicrobial activity against *Staphylococcus aureus*, further comprising one or more bacteriophages or additional proteins effective against bacteria other than *Staphylococcus aureus*.

28. The pharmaceutical composition of claim 21, comprising an isolated protein having the amino acid sequence of SEQ ID NOS:761-816, or a fragment, variant or derivative thereof having antibacterial or antimicrobial activity against *Acinetobacter baumannii*, further comprising one or more bacteriophages or additional proteins effective against *Acinetobacter baumannii*.

29. The pharmaceutical composition of claim 21, comprising an isolated protein having the amino acid sequence of SEQ ID NOS:761-816, or a fragment, variant or derivative thereof having antibacterial or antimicrobial activity against *Acinetobacter baumannii*, further comprising one or more bacteriophages or additional proteins effective against bacteria other than *Acinetobacter baumannii*.

30. An isolated nucleic acid comprising a nucleotide sequence encoding the protein of claim 11 or 17.

31. A method of treating or preventing a bacterial infection in a subject in need thereof comprising administering to said subject a therapeutically amount of the pharmaceutical composition of claim 2 or 21.

32. The method of claim 31 wherein said bacterial infection is an infection by one or more of *Acinetobacter baumanni, Enterococcus faecalis, Enterococcus faecium, Pseudomonas aeruginosa* and *Staphylococcus aureus.*

33. The method of claim 31 wherein said bacterial infection is an infection by a bacterium other than *Acinetobacter baumanni, Enterococcus faecalis, Enterococcus faecium, Pseudomonas aeruginosa* and *Staphylococcus aureus.*

34. The method of claim 31, wherein the infection is a nosocomial infection.

35. The method of claim 31, wherein the composition is administered topically.

36. The method of claim 31, wherein the subject is a mammal.

37. The method of claim 36, wherein the mammal is a human.

38. The method of claim 31, wherein the infection treated is an infection of the skin.

39. The method of claim 38, wherein said infection of the skin is an infection associated with a diabetic foot ulcer.

40. A method for diagnosing the causative agent of a bacterial infection comprising

(i) culturing a tissue sample from a patient;

(ii) contacting the culture of step(i) with the bacteriophage or protein of claim 1, 11 or 17;

(iii) monitoring for evidence of growth or lysis of the culture

wherein evidence of lysis of the culture indicatives that the culture comprises a species or strain of bacteria that is known to be susceptible to the bacteriophage or polypeptide used in step (ii).

41. The method of claim 40, wherein the tissue sample is a sample of blood, fluid, tissue biopsy or swab collected from said patient.

42. A method for reducing or inhibiting the colonization or growth of bacteria on a surface comprising contacting said surface with a bacteriophage or polypeptide of claim 1, 11 or 17.

43. The method of claim 42, wherein said surface is the skin or a mucus membrane of a mammal.

44. The method of claim 43, wherein said mammal is a human.

45. The method of claim 42, wherein said surface is the surface of a hospital apparatus or a piece of hospital equipment.

46. The method of claim 45, wherein said apparatus or equipment is a surgical apparatus or piece of surgical equipment.